FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2946482102> ?p ?o ?g. }

• W2946482102 endingPage "77" @default.
• W2946482102 startingPage "70" @default.
• W2946482102 abstract "Kratom (Mitragyna speciosa) is a tree-like plant indigenous to Southeast Asia. Its leaves, and the teas brewed from them have long been used by people in that region to stave off fatigue and to manage pain and opioid withdrawal. Evidence suggests kratom is being increasingly used by people in the United States and Europe for the self-management of opioid withdrawal and treatment of pain. Recent studies have confirmed that kratom and its chemical constituents have potentially useful pharmacological actions. However, there have also been increasing numbers of reports of adverse effects resulting from use of kratom products. In August 2016, the US Drug Enforcement Administration announced plans to classify kratom and its mitragynine constituents as Schedule I Controlled Substances, a move that triggered a massive response from pro-kratom advocates. The debate regarding the risks, and benefits and safety of kratom continues to intensify. Kratom proponents tout kratom as a safer and less addictive alternative to opioids for the management of pain and opioid addiction. The anti-kratom faction argues that kratom, itself, is a dangerous and addictive drug that ought to be banned. Given the widespread use of kratom and the extensive media attention it is receiving, it is important for physicians, scientists and policy makers to be knowledgeable about the subject. The purpose of this commentary is to update readers about recent developments and controversies in this rapidly evolving area. All of the authors are engaged in various aspects of kratom research and it is our intention to provide a fair and balanced overview that can form the basis for informed decisions on kratom policy. Our conclusions from these analyses are: (a) User reports and results of preclinical studies in animals strongly suggest that kratom and its main constituent alkaloid, mitragynine may have useful activity in alleviating pain and managing symptoms of opioid withdrawal, even though well-controlled clinical trials have yet to be done. (b) Even though kratom lacks many of the toxicities of classic opioids, there are legitimate concerns about the safety and lack of quality control of purported “kratom” products that are being sold in the US. (c) The issues regarding the safety and efficacy of kratom and its mitragynine constituent can only be resolved by additional research. Classification of the Mitragyna alkaloids as Schedule I controlled substances would substantially impede this important research on kratom." @default.
• W2946482102 created "2019-05-29" @default.
• W2946482102 creator A5009378433 @default.
• W2946482102 creator A5018396156 @default.
• W2946482102 creator A5024813047 @default.
• W2946482102 creator A5030268279 @default.
• W2946482102 creator A5034406366 @default.
• W2946482102 creator A5044827754 @default.
• W2946482102 creator A5058977080 @default.
• W2946482102 creator A5068085470 @default.
• W2946482102 creator A5070757560 @default.
• W2946482102 creator A5076547847 @default.
• W2946482102 creator A5077225690 @default.
• W2946482102 date "2019-08-01" @default.
• W2946482102 modified "2023-10-01" @default.
• W2946482102 title "Kratom policy: The challenge of balancing therapeutic potential with public safety" @default.
• W2946482102 cites W1534015176 @default.
• W2946482102 cites W1551363431 @default.
• W2946482102 cites W1831950147 @default.
• W2946482102 cites W1894954374 @default.
• W2946482102 cites W1896831508 @default.
• W2946482102 cites W1959635993 @default.
• W2946482102 cites W1964903000 @default.
• W2946482102 cites W1974049279 @default.
• W2946482102 cites W1975784887 @default.
• W2946482102 cites W1977294556 @default.
• W2946482102 cites W2003704830 @default.
• W2946482102 cites W2008653106 @default.
• W2946482102 cites W2013033269 @default.
• W2946482102 cites W2030996161 @default.
• W2946482102 cites W2034360314 @default.
• W2946482102 cites W2052345694 @default.
• W2946482102 cites W2056901704 @default.
• W2946482102 cites W2062476288 @default.
• W2946482102 cites W2063294977 @default.
• W2946482102 cites W2066166905 @default.
• W2946482102 cites W2076047141 @default.
• W2946482102 cites W2088155288 @default.
• W2946482102 cites W2089598859 @default.
• W2946482102 cites W2112497272 @default.
• W2946482102 cites W2114503230 @default.
• W2946482102 cites W2116697656 @default.
• W2946482102 cites W2122692346 @default.
• W2946482102 cites W2134991103 @default.
• W2946482102 cites W2138107386 @default.
• W2946482102 cites W2143224165 @default.
• W2946482102 cites W2146368136 @default.
• W2946482102 cites W2151491015 @default.
• W2946482102 cites W2166575463 @default.
• W2946482102 cites W2168181065 @default.
• W2946482102 cites W2173132441 @default.
• W2946482102 cites W2176160743 @default.
• W2946482102 cites W2273422362 @default.
• W2946482102 cites W2318945287 @default.
• W2946482102 cites W2319317039 @default.
• W2946482102 cites W2328465631 @default.
• W2946482102 cites W2336801570 @default.
• W2946482102 cites W2347577139 @default.
• W2946482102 cites W2398657959 @default.
• W2946482102 cites W2411655243 @default.
• W2946482102 cites W2478441048 @default.
• W2946482102 cites W2507665026 @default.
• W2946482102 cites W2523711035 @default.
• W2946482102 cites W2536844334 @default.
• W2946482102 cites W2559437484 @default.
• W2946482102 cites W2612936264 @default.
• W2946482102 cites W2745351785 @default.
• W2946482102 cites W2754227946 @default.
• W2946482102 cites W2765783316 @default.
• W2946482102 cites W2770319189 @default.
• W2946482102 cites W2772290079 @default.
• W2946482102 cites W2772739405 @default.
• W2946482102 cites W2776352998 @default.
• W2946482102 cites W2793295211 @default.
• W2946482102 cites W2793644042 @default.
• W2946482102 cites W2810775807 @default.
• W2946482102 cites W2811416035 @default.
• W2946482102 cites W2884215484 @default.
• W2946482102 cites W2898879786 @default.
• W2946482102 cites W2907450060 @default.
• W2946482102 cites W2920592781 @default.
• W2946482102 cites W78722479 @default.
• W2946482102 cites W9887492 @default.
• W2946482102 doi "https://doi.org/10.1016/j.drugpo.2019.05.003" @default.
• W2946482102 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7881941" @default.
• W2946482102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31103778" @default.
• W2946482102 hasPublicationYear "2019" @default.
• W2946482102 type Work @default.
• W2946482102 sameAs 2946482102 @default.
• W2946482102 citedByCount "72" @default.
• W2946482102 countsByYear W29464821022019 @default.
• W2946482102 countsByYear W29464821022020 @default.
• W2946482102 countsByYear W29464821022021 @default.
• W2946482102 countsByYear W29464821022022 @default.
• W2946482102 countsByYear W29464821022023 @default.
• W2946482102 crossrefType "journal-article" @default.
• W2946482102 hasAuthorship W2946482102A5009378433 @default.
• W2946482102 hasAuthorship W2946482102A5018396156 @default.

• next